Protara Therapeutics Inc expected to post a loss of 45 cents a share - Earnings Preview

Protara Therapeutics

28/04/2025 14:02

Protara Therapeutics Inc TARA.OQ TARA.O is expected to show no change in quarterly revenue when it reports  results on April 30 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Protara Therapeutics Inc is for a loss of 45 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Protara Therapeutics Inc is $23.00​, above​ its last closing price of $4.32. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATEÂŪ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.56
-0.56
-0.49
Beat
13.3
Sep. 30 2024
-0.52
-0.52
-0.50
Beat
3.8
Jun. 30 2024
-0.96
-0.80
-0.45
Beat
43.8​
Mar. 31 2024
-0.86
-0.92
-0.97
Missed
-5.4
​​Dec. 31 2023
-0.92
-0.90
Beat
1.9
Sep. 30 2023
-1.04
-0.98
-0.87
Beat
11.2​
Jun. 30 2023
-0.88
-0.87
-1.00
Missed
-14.3
Mar. 31 2023
-0.91
-0.88
-0.80
Beat
8.8

This summary was machine generated April 28 at 13:02 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)